PPARG and type 2 diabetes mellitus: Thiazolidinediones (TZDs) are synthetic peroxisome proliferator-activated receptor-γ (PPARγ) agonists that have been widely used in treating type 2 diabetes and can inhibit cellular growth through PPARγ-dependent or -independent pathways.